The human colon adenocarcinoma cell line HT-29 in culture exhibits a cyclic AMP production system highly sensitive to vasoactive intestinal peptide (VIP), making cells a unique cultured cell system for studying the mechanism of VIP action [Laburthe, Rousset, Boissard, Chevalier, Zweibaum & Rosselin (1978) Proc. Natl. Acad. Sci. U.S. A. 75, 2772-2775]. The quantitative characteristics of VIP receptors in HT-29 cells and their structural requirement and molecular size were studied. 1251-labelled VIP bound in a time-dependent manner to HT-29 cell homogenates. At equilibrium (60 min incubation at 30°C), unlabelled VIP in the 0.01-10 nm concentration range competed with 125I-VIP for binding to cell homogenates. Scatchard analysis of binding data gave a straight line, indicating that VIP bound to a single population of sites with a KD of 0.12 + 0.02 nm and a capacity of 120 + 9 fmol/mg of protein. The structural requirement of these receptors was studied with peptides structurally related to VIP, either natural or synthetic. Several peptides inhibited 125I-VIP binding to HT-29 cell homogenates with the following order of potency, which is typical of the human VIP receptor: VIP (IC50 = 0.1 nM) > VIP-(2-28)-peptide (IC50 = 13 nM) > human growth hormone releasing factor (IC50 = 56 nM) > peptide histidine isoleucine amide (IC50 = 80 nM) > secretin (IC50 > 10000 nM). To characterize the molecular component(s) of the VIP receptor in HT-29 cells, 125I-VIP was covalently bound to cell homogenates by using the cross-linker dithiobis(succinimidyl propionate). Sodium dodecyl sulphate/polyacrylamide-gel autoradiographic studies of affinity-labelled cell homogenates revealed two major bands, corresponding to 125I-VIP-protein complexes of Mr 66000 and 16000. The labelling of the Mr-66000 component was specific, since it was abolished by native VIP, whereas that of the Mr-16000 component was not. Densitometric scanning of autoradiographs indicated that the labelling of the Mr-66 000 complex was inhibited by low VIP concentrations in the 0.1-10 nm range (IC50 = 0.6 nM), but was unaffected by 1 /LM-glucagon or octapeptide of cholecystokinin. It was also decreased by VIP-(2-28)-peptide with a potency 1 % that of VIP. Assuming that one molecule of 1251-VIP bound per molecule of protein, one protein of Mr 63000 was identified as a component of the VIP receptor in HT-29 cells.
INTRODUCTION
The vasoactive intestinal peptide (VIP) is a neuropeptide widely distributed in the organism where it regulates various peripheral and central functions (Said, 1982) . VIP triggers biological responses through specific binding to cell surface receptors (Laburthe et al., 1978 a) . The functional properties of VIP receptors as well as their coupling to adenylate cyclase have been described extensively, in particular in the rat intestinal epithelium (Laburthe & Dupont, 1982) . As early as 1978, we reported that VIP receptors are present in cell lines derived from human colon adenocarcinoma (Laburthe et al., 1978 b) and later confirmed their wide distribution in human colonic cancerous cells (Laburthe et al., 1980a) . Owing to the dramatic sensitivity of its cyclic AMP production system to VIP, we proposed that one of these cell lines, HT-29, may be a unique cellular model in culture for studying the mechanism of VIP action (Laburthe et al., 1978b) . Indeed, cells have been subsequently used by us and others for various purposes such as the transfer of VIP receptors from HT-29 cells to the adenylate cyclase in another cell (Laburthe et al., 1979) , the study of VIP control of protein kinases (Marvaldi et al., 1979) and glycogenolysis (Rousset et al., 1981) , the elaboration of a highly sensitive bioassay for VIP (Laburthe et al., 1980b) and the generation of antibodies that partially antagonize the VIP-stimulated adenylate cyclase activity (Pichon et al., 1983) . In spite of the frequent use of HT-29 cells for studying the dynamics of VIP receptors, very little is known about their basic properties in HT-29.
The present work had three main objectives. (Laburthe et al., 1983 , but compare well with those reported in normal human colon (Laburthe et al., 1983; .
EXPERIMENTAL Materials
Porcine VIP was provided by Professor V. Mutt (Karolinska Institute, Stockholm, Sweden). 125I-labelled VIP was prepared by the chloramine-T method (Hunter & Greenwood, 1962) , at a specific radioactivity of 250 Ci/g, as described by Laburthe et al., (1977) . It displays the same activity as native VIP in stimulating cyclic AMP accumulation in the cultured cell line HT-29 (Laburthe et al., 1978b) . Synthetic VIP-(2-28)-peptide was synthesized by a solid-phase method (Fournier et al., 1984) Cell culture and preparation of particulate fraction from cell homogenate
The human colon adenocarcinoma cell line HT-29 (Fogh & Trempe, 1975) (v/v) fetal bovine serum and incubated at 37°C in a C02/air (1:9) atmosphere. The medium was changed daily. Cells were harvested on day 4-5 (in exponential growth phase) with 3 mM-EDTA in 0.13 M-phosphatebuffered saline pH 7.2. They were centrifuged (2000 g for 5 min at 4°C) and the cell pellet was resuspended in hypo-osmotic 5 mM-Hepes buffer, pH 7.5. After 15 min in ice, the cell suspension was homogenized with 30 strokes of a Dounce homogenizer. The homogenate was centrifuged at 30000 g for 10 min. The resulting pellet was washed three times in 60 mM-Hepes buffer, pH 7.5, and kept at -80°C until use. This membrane/particulate fraction obtained from cell homogenate will be referred to as particulate preparation. Proteins were determined by the method of Bradford (1976) , with bovine serum albumin as standard.
Binding of 1251-VIP
Particulate preparation (about 100 /tg/ml) was incubated at equilibrium for 60 min at 30°C with 1251-VIP (0.05 nm for binding studies or 0.3 nm for cross-linking studies) and other compounds when necessary in 60 mM-Hepes buffer, pH 7.5, containing 2 % (w/v) bovine serum albumin and 0.1 % (w/v) bacitracin. The reaction was stopped by transferring the incubation medium to an excess of ice-cold buffer, and homogenate-bound labelled VIP was separated by centrifugation at 30000 g for 10 min at 4 'C. For each unlabelled peptide the IC50 was defined as the concentration of peptide which half-maximally inhibited the specific binding of 1251-VIP. Cross-linking conditions and SDS/polyacrylamide-gel electrophoresis of proteins Particulate preparation containing bound 1251-VIP were suspended in 1 ml of 60 mM-Hepes buffer, pH 7.5, and incubated for 15 min at 4 'C in the presence of 1 mM-DTSP as described by Laburthe et al. (1984) . At the end of the incubation, the reaction was quenched by adding 500,l of ice-cold 60 mM-Hepes buffer, pH 7.5, containing 60 mM-lysine. The cross-linked material was pelleted at 20000 g for 15 min, and the resulting pellets were suspended by five successive passages through a 25-gauge needle in 60 mM-Tris/HCl buffer, pH 6.8, Bromo- phenol Blue and 30 (w/v) SDS. After heating at 60 'C for 30 min, the suspension was centrifuged at 40000 g for 15 min and aliquots of the supernatant were applied to a 5-200 %-polyacrylamide slab gel (1.5 mm thick), in accordance with the Laemmli (1970) method with a 30 %-acrylamide stacking gel. The gels were run, fixed, stained and destained as described by Laburthe et al., (1984) . They were dried and exposed for 3-8 days at -80 'C to a Trimax type XM film (3M) with a Trimax intensifying screen. Autoradiographs were scanned at 600nm with a spectrophotometer connected to an Omni-Scribe recorder (Houston Instruments).
RESULTS
Specific binding of 1251-VIP to particulate preparation obtained from HT-29 cell is time-dependent (Fig. 1) 2), half-maximal inhibition being obtained at 0.10+0.01 nM (mean+ S.E.M. for seven experiments). Scatchard analysis gives a straight line (Fig. 3) (Fig. 2) phoresis, the resulting autoradiographs were scanned as described by Laburthe et al. (1984) . The to 125I-VIP-protein complexes of Mr 66000 and 16000 (Fig. 4, lane a) . The specificity of labelling of these bands is tested by adding native VIP (0.1 M) with 1251-VIP. The labelling of the Mr-66 000 component is completely abolished by native VIP, whereas that of the M4-16000 component is poorly affected (Fig. 4, lane b) . This indicates that the Mr-66 000 component is involved in the specific binding of VIP to HT-29 cells, whereas the Mr-16000 component is not specifically labelled by 1251-VIP. As shown in Fig. 4 (lanes c and d) , the addition of 1 /M glucagon or 1 gM-octapeptide of cholecystokinin does not affect the labelling of the Mr-66 000 component, indicating its peptide specificity. The concentrationdependence of VIP binding to the Mr-66000 component is tested by adding increasing concentrations of native VIP with 1251-VIP. Integration of the peak obtained by micro-densitometric scanning of autoradiographs shows that the covalent labelling of the Mr-66000 component is inhibited by native VIP in the concentration range 0.1-10 nM (Fig. 5) , half-maximal inhibition occurring at 0.6 + 0.1 nm (mean + S.E.M. for four experiments). The structural requirement of the Mr-66000 component is tested with the most potent VIP agonist, i.e. VIP-(2-28)-peptide (see Fig. 2 ). VIP-(2-28)-peptide is about 100 times less potent than VIP in inhibiting the covalent labelling of the Mr-66 000 component (Fig. 5) . This compares well with the relative potency of the two peptides in competing with 1251-VIP for binding to HT-29 cells.
DISCUSSION
The present paper indicates that the human colon adenocarcinoma cell line HT-29 in culture expresses a single population of high-affinity binding sites for the neuropeptide VIP. The dissociation constant of these sites, i.e. 0.12 nm, compares well with the ED50 of VIP in stimulating cyclic AMP production, i.e. 0.3 nM (Laburthe et al., 1978b) or protein kinase activity, i.e. 0.1 nM (Marvaldi et al., 1979) or glycogenolysis, i.e. approx. 0.3 nM (Rousset et al., 1981) Fig. 5 ), within the dose-response curve for both the stimulation of cyclic AMP production (Laburthe et al., 1978b) and the saturation of VIP-binding site (see Figs. 2 and 3) (Broyart et al., 1981) , corresponding to two different VIP-binding proteins identified by covalent cross-linking as a Mr-63 000 protein and a Mr-30 000 protein respectively . The reason why the low-affinity binding site is not observed in HT-29 cells is unknown. What is clear, however, is that the molecular size of the VIP receptor in HT-29 cells, i.e. 63000 Da, is identical with that of the high-affinity VIP-binding site mediating adenylate cyclase activity by VIP in normal human colonic cells . This molecular size is in contrast different from that determined in rat intestinal epithelial cells, i.e. 73000 Da (Laburthe et al., 19&4) , and appears be typical of the human intestine, either normal or transformed. As far as the molecular size of the VIP receptor is concerned, it thus appears that HT-29 cells retain their species specificity in the expression of VIP receptors. They also retain their species specificity in another feature, the structural requirement of the VIP-recognition site. Indeed, the relative affinities of the different VIP agonists, i.e. VIP > VIP-(2-28)-peptide > hGRF > PHI > secretin, in cells is identical with that described previously in plasma membranes from normal human colonic cells, but contrasts markedly with that described in rat intestinal epithelium, i.e. VIP > PHI > VIP-(2-28)-peptide > secretin > hGRF (Laburthe et al., 1983; Couvineau et al., 1984) . Like VIP receptors in rat or human intestine (Couvineau et al., 1984) , VIP receptors in HT-29 cells are very susceptible to the absence of the N-terminal histidine [as in VIP-(2-28)-peptide], since the deletion of this amino acid results in a 100-fold decrease in affinity (see Fig. 2) i for rat VIP receptors and further confirms that the VIP receptor in the human has evolved towards a high degree of specificity of its recognition site for the members of the so-called VIP-secretin family (Laburthe et al., 1983 .
In conclusion, the present work indicates a Mr-63 000 protein is involved in the specific binding of VIP to one single population of high-affinity sites in the human colon adenocarcinoma cell line HT-29. These receptors display structural requirements and molecular size identical with those of the high-affinity VIP receptor observed in normal human colonic cells. This further indicates the validity of the HT-29 cell line for studying VIP-receptor structure and function.
